**This is a thoughtfully designed, academically grounded strategy.** The core idea — purifying momentum by stripping out market beta via residuals — is one of the cleaner refinements in the momentum literature, and x03 implements it in a practical, transparent way.

### What stands out as strong

**The residual approach is genuinely better-engineered momentum.**  
Plain momentum (raw past returns) embeds a hidden, time-varying beta bet. When the market has been rising, high-momentum stocks tend to be high-beta names that simply amplified the rally. When the market reverses hard (especially after a bear market), that embedded leverage turns against you — this is a major driver of the infamous momentum crashes (e.g., early 2009). 

By ranking on the **information ratio of CAPM residuals** (`mean(ε) / std(ε)` over the 252-21 day window), x03 removes that systematic component. Academic work (Blitz, Huij & Martens 2011 and follow-ups; Huij & Lansdorp 2017; various Robeco papers) consistently shows residual/idiosyncratic momentum delivers:
- Similar or slightly lower gross returns
- **Much lower volatility**
- **Higher Sharpe ratios** (often roughly double in long-short tests)
- Shallower drawdowns and reduced crash severity
- Lower time-varying factor exposures

Your in-sample comparison (beta ~1.45 → ~1.08, max DD ~36% → ~23%, Sharpe 0.81 → 0.89) aligns closely with what the literature reports for this family of strategies. The risk reduction is the real win here, not some magical new alpha source.

**Implementation details are sensible and conservative:**
- Liquidity/price/history gates are prudent and prevent the strategy from living in illiquid micro-caps or recent IPOs.
- Skip-month (standard in momentum research) avoids short-term reversal noise.
- Equal-weight top 50 + pure time-based monthly rebalance avoids overfitting via stops, targets, or score-weighting.
- No sector/industry inputs — any concentration is emergent, which is intellectually honest.
- Transparent about evidence level: plain momentum family has solid OOS (including 2025), x03 has strong in-sample confirmation of the risk improvement but awaits its own clean holdout year.

This reads like something built by people who understand both the academic literature and practical trading constraints.

### Areas worth probing / potential weaknesses

**Transaction costs and turnover are the biggest unaddressed variable.**  
Monthly rebalancing of 50 equal-weighted names implies meaningful turnover (winners get sold, new names enter). Even with liquid names ($10M+ ADV), bid-ask spreads + market impact + commissions can erode a large chunk of a ~0.9 Sharpe edge. Many residual momentum backtests in the literature are gross of costs. I’d want to see:
- Realistic turnover numbers
- Estimated/actual all-in costs per rebalance
- Net Sharpe / net drawdowns after costs

**Capacity and slippage at scale.**  
Top 50 equal-weight works fine at modest AUM, but as size grows you start competing for liquidity in the 40th–50th names. The $10M ADV gate helps, but it’s still a constraint worth stress-testing.

**It’s still a momentum strategy.**  
Correlation to plain momentum is high (~0.95 as you note). It will still suffer in momentum-crash regimes, just less severely. It won’t magically protect you in a broad equity bear market (beta ~1.08 is still full equity exposure). Long-only means no hedge on the short side.

**Single-factor residual is a limitation (acknowledged).**  
Using only CAPM leaves some size/value/sector/style bleed in the “idiosyncratic” bucket. Multi-factor residuals (FF3/5 or more) often improve things further in academic tests. That’s a natural next step.

**OOS status for x03 specifically.**  
You’re appropriately cautious here. The family has good evidence; the specific risk-improved variant is pre-registered and in-sample strong, but a fresh sealed year (~2027) will be the real test. That’s the right way to frame it.

**Other practical questions**
- How sensitive are results to the exact parameters (top 50 vs top 100, exact window, equal vs score weight)?
- What does sector/industry concentration look like over time? Any unintended style tilts?
- Live track record since the UI went live — how has it behaved in 2025–2026 conditions?
- Full backtest suite: turnover, win rate, return distribution, comparison vs SPY and a plain momentum benchmark (e.g., MTUM or a simple 12-1 implementation).

### Bottom line

This is one of the more credible systematic momentum variants I’ve seen described. It takes a well-documented academic improvement (residual momentum) and implements it cleanly for long-only use with realistic constraints. The value proposition is **better risk-adjusted participation in the momentum premium**, not outsized alpha or crash-proofing.

Expectations should stay modest: something in the neighborhood of equity-like returns with a meaningfully better Sharpe and shallower worst-case than naive momentum. That’s a legitimate edge for the right investor — especially if costs are well-controlled and position sizing respects capacity.

It’s not “set and forget magic.” Like all quant strategies, it will have multi-year stretches of underperformance or flat results. The transparency in the document (especially the evidence caveats) is a good sign.

If you have more details (full backtest stats with costs, live performance, turnover numbers, or the exact regression implementation), I can give a more granular take. Overall, this looks like serious, professional-grade work on a real phenomenon.